The stock of Nextcure Inc (NXTC) has gone up by 0.79% for the week, with a 52.53% rise in the past month and a -41.32% drop in the past quarter. The volatility ratio for the week is 15.38%, and the volatility levels for the past 30 days are 17.21% for NXTC. The simple moving average for the past 20 days is 9.49% for NXTC’s stock, with a -56.68% simple moving average for the past 200 days.
Is It Worth Investing in Nextcure Inc (NASDAQ: NXTC) Right Now?
Company’s 36-month beta value is 1.04.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NXTC is 21.87M, and currently, short sellers hold a 0.84% ratio of that floaft. The average trading volume of NXTC on May 12, 2025 was 144.53K shares.
NXTC) stock’s latest price update
The stock price of Nextcure Inc (NASDAQ: NXTC) has jumped by 15.84 compared to previous close of 0.38. Despite this, the company has seen a gain of 0.79% in its stock price over the last five trading days. globenewswire.com reported 2025-05-01 that Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results.
Analysts’ Opinion of NXTC
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see NXTC reach a price target of $16. The rating they have provided for NXTC stocks is “Buy” according to the report published on March 01st, 2022.
Truist gave a rating of “Buy” to NXTC, setting the target price at $19 in the report published on March 05th of the previous year.
NXTC Trading at -11.71% from the 50-Day Moving Average
After a stumble in the market that brought NXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.49% of loss for the given period.
Volatility was left at 17.21%, however, over the last 30 days, the volatility rate increased by 15.38%, as shares surge +65.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.00% lower at present.
During the last 5 trading sessions, NXTC rose by +0.79%, which changed the moving average for the period of 200-days by -72.13% in comparison to the 20-day moving average, which settled at $0.4073. In addition, Nextcure Inc saw -42.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NXTC
The total capital return value is set at -0.86. Equity return is now at value -63.94, with -54.33 for asset returns.
Based on Nextcure Inc (NXTC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -8.38.
Currently, EBITDA for the company is -52.79 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.26.
Conclusion
In a nutshell, Nextcure Inc (NXTC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
